Day One Biopharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
Day One Biopharmaceuticals, Inc. carries a market capitalization of 2.22B, placing it among publicly traded companies globally. Its enterprise value stands at 522.14M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.22B |
| Enterprise Value | 522.14M |
Share Statistics
Day One Biopharmaceuticals, Inc. currently has 102.98M shares outstanding.
| Shares Outstanding | 102.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 6.07, and the price-to-book ratio stands at -1.45.
| PE Ratio | N/A |
| PS Ratio | 6.07 |
| PB Ratio | -1.45 |
| P/TBV Ratio | 2.27 |
| P/FCF Ratio | -9.61 |
| P/OCF Ratio | -9.26 |
Enterprise Valuation
| EV / Sales | 3.30 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 48.48 |
Financial Position
Day One Biopharmaceuticals, Inc. maintains a current ratio of 8.02, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.02 |
| Quick Ratio | 7.73 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -19.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.57 |
Taxes
| Income Tax | -1.98M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Day One Biopharmaceuticals, Inc.'s stock has gained approximately 241.74603% over the past 52 weeks. The 50-day moving average sits at 18.21, while the 200-day moving average is 10.72.
| Beta (5Y) | N/A |
| 52-Week Price Change | 241.74603% |
| 50-Day Moving Average | 18.21 |
| 200-Day Moving Average | 10.72 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Day One Biopharmaceuticals, Inc. generated 158.18M in revenue and converted that into -107.32M in net income, yielding earnings per share of -1.04. EBITDA reached -123.96M, while operating income came in at -127.75M.
| Revenue | 158.18M |
| Gross Profit | 140.97M |
| Operating Income | -127.75M |
| Pretax Income | -109.30M |
| Net Income | -107.32M |
| EBITDA | -123.96M |
| EBIT | -127.75M |
| Earnings Per Share (EPS) | -1.04 |
Balance Sheet
Day One Biopharmaceuticals, Inc. holds 441.11M in cash and equivalents against 2.79M in total debt, resulting in a net debt position of -197.08M. Total book value stands at -661.39M, with working capital of 424.58M providing operational flexibility.
| Cash & Cash Equivalents | 441.11M |
| Total Debt | 2.79M |
| Net Debt | -197.08M |
| Equity (Book Value) | -661.39M |
| Book Value Per Share | -6.42 |
| Working Capital | 424.58M |
Cash Flow
Day One Biopharmaceuticals, Inc. produced -103.76M in operating cash flow over the past twelve months. After subtracting -3.82M in capital expenditures, free cash flow totaled -107.58M - equivalent to -1.04 per share.
| Operating Cash Flow | -103.76M |
| Capital Expenditures | -3.82M |
| Free Cash Flow | -107.58M |
| FCF Per Share | -1.04 |
Margins
Day One Biopharmaceuticals, Inc. operates with a gross margin of 89.12, reflecting its pricing power and cost economics. The operating margin of -80.76 and net profit margin of -67.85 provide insight into operational efficiency.
| Gross Margin | 89.12 |
| Operating Margin | -80.76 |
| Pretax Margin | -69.10 |
| Profit Margin | -67.85 |
| EBITDA Margin | -78.37 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.13 |
| FCF Yield | -10.41 |
Scores
Day One Biopharmaceuticals, Inc. posts an Altman Z-Score of 7.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.26 |